论文部分内容阅读
将所有病例分为正常糖耐量组(NGT)30例、1型糖尿病组(T_1DM)25例、2型糖尿病组(T_2DM)30例,长秀霖联合诺和锐治疗1月后,检测各组血清omentin-1、Visfatin水平。结果治疗后,血清Visfatin水平T2DM组及T_1DM组接近于NGT组((均P>0.05),T_22DM组显著低于T_1DM组(均P<0.05)。血清omentin-1水平T2DM组与IGT组接近于于NGT组((均P>0.05),T_2DM组显著高于T_1DM组(均P<0.05)。结论长秀霖联合诺和锐强化治疗后改善2型糖尿病患者血清omentin-1、Visfatin水平。进一步证实血清omentin-1、Visfatin与糖尿病自身免疫、胰岛β细胞功能及血糖水平密切相关。
All cases were divided into normal glucose tolerance group (NGT) 30 cases, type 1 diabetes group (T_1DM) in 25 cases, type 2 diabetes group (T_2DM) in 30 cases, Changxiu Lin and Novolin treatment for 1 month, Serum omentin-1, Visfatin levels. Results Serum visfatin levels in T2DM group and T 1DM group were significantly higher than those in NGT group (all P> 0.05), while those in T 2DM group were significantly lower than those in T 1DM group (all P <0.05) .Serum levels of omentin-1 in T2DM group and IGT group were similar In NGT group (all P> 0.05), T 2DM group was significantly higher than that in T 1 DM group (all P <0.05) .Conclusion Chang-lin combined with Norvan-sharp treatment can improve serum levels of omentin-1 and Visfatin in type 2 diabetic patients Confirmed that serum omentin-1, Visfatin and diabetes autoimmune, pancreatic β-cell function and blood glucose levels are closely related.